We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BD's (BDX) Latest Product to Offer Wider Access to Researchers
Read MoreHide Full Article
Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, recently announced the global commercial release of new cell sorters, the new BD FACSDiscover S8 Cell Sorters. This will likely enable researchers in a broader range of fields (including cell biology, cancer research and immunology) to provide insights that were previously invisible in traditional flow cytometry experiments.
The new BD FACSDiscover S8 Cell Sorters feature BD CellView Image Technology and BD SpectralFX Technology. This, according to the company, is bringing breakthrough innovations in real-time imaging and spectral flow cytometry to the market.
The family of BD FACSDiscover Cell Sorters is now available to order through local sales representatives. The company will feature the family of BD FACSDiscover Cell Sorters at upcoming conferences, beginning with the ongoing American Association for Cancer Research Annual Meeting.
The latest announcement is expected to significantly strengthen BD’s foothold in the global Biosciences (BDB) business unit, which is part of its broader Life Sciences arm.
Significance of the Launch
The three- and four-laser additions to the BD FACSDiscover S8 Cell Sorter family complement the five-laser instrument launched in 2023. This is expected to provide scientists greater access, options and flexibility to incorporate real-time imaging and spectral cell sorting technology in their labs.
Per an expert familiar with the use of the FACSDiscover S8 Cell Sorters, the instrument was seamlessly configured with respect to the number of lasers and imaging capabilities for his research in cellular biology. Due to the presence of the same sorting speed and software capabilities as the five-laser unit, experiments were extremely scalable on the easy-to-use instrument.
Industry Prospects
Per a report by MarketsandMarkets, the global flow cytometry market was valued at $4.7 billion in 2023 and is anticipated to reach $7 billion by 2028 at a CAGR of 8.3%. Factors like the growing prevalence of cancer and the growing adoption of flow cytometry in clinical applications are likely to drive the market.
Given the market potential, the latest launch is expected to significantly strengthen BD’s business worldwide.
Notable Developments in Life Sciences Arm
In February, BD announced a strategic partnership with Camtech Health to advance cervical cancer screening by offering the first-ever option for women in Singapore to self-collect a sample privately in their homes.
In January, BD announced a strategic collaboration agreement with Techcyte. The tie-up aims to offer an artificial intelligence-based algorithm that guides cytologists and pathologists to efficiently and effectively identify evidence of cervical cancer and pre-cancer using whole-slide imaging.
BD reported its first-quarter fiscal 2024 results, wherein robust performances by the BDB unit were witnessed. The Integrated Diagnostic Solutions (IDS) business unit saw high single-digit growth in Microbiology platforms and strong double-digit growth from Molecular In Vitro Diagnostic assays leveraging the BD COR System and BD Max System install base. During the quarter, the IDS unit received the FDA’s 510(k) clearance for the BD MiniDraw Capillary Blood Collection System.
Price Performance
Shares of BD have lost 2.9% in the past year against the industry’s 9.7% rise and the S&P 500's 27.1% growth.
Image Source: Zacks Investment Research
Zacks Rank & Other Key Picks
Currently, BD carries a Zacks Rank #2 (Buy).
A few other top-ranked stocks in the broader medical space are DaVita Inc. (DVA - Free Report) , Cardinal Health, Inc. (CAH - Free Report) and LeMaitre Vascular, Inc. (LMAT - Free Report) .
DaVita, flaunting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 12.1%. DVA’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 35.6%. You can see the complete list of today’s Zacks #1 Rank stocks here.
DaVita’s shares have gained 61.6% compared with the industry’s 17.6% rise in the past year.
Cardinal Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 14.2%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average being 15.6%.
Cardinal Health has gained 38.1% compared with the industry’s 9.7% rise in the past year.
LeMaitre Vascular, sporting a Zacks Rank of 1 at present, has an estimated long-term growth rate of 14%. LMAT’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 8.9%.
LeMaitre Vascular’s shares have rallied 20.8% compared with the industry’s 2.6% rise in the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
BD's (BDX) Latest Product to Offer Wider Access to Researchers
Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, recently announced the global commercial release of new cell sorters, the new BD FACSDiscover S8 Cell Sorters. This will likely enable researchers in a broader range of fields (including cell biology, cancer research and immunology) to provide insights that were previously invisible in traditional flow cytometry experiments.
The new BD FACSDiscover S8 Cell Sorters feature BD CellView Image Technology and BD SpectralFX Technology. This, according to the company, is bringing breakthrough innovations in real-time imaging and spectral flow cytometry to the market.
The family of BD FACSDiscover Cell Sorters is now available to order through local sales representatives. The company will feature the family of BD FACSDiscover Cell Sorters at upcoming conferences, beginning with the ongoing American Association for Cancer Research Annual Meeting.
The latest announcement is expected to significantly strengthen BD’s foothold in the global Biosciences (BDB) business unit, which is part of its broader Life Sciences arm.
Significance of the Launch
The three- and four-laser additions to the BD FACSDiscover S8 Cell Sorter family complement the five-laser instrument launched in 2023. This is expected to provide scientists greater access, options and flexibility to incorporate real-time imaging and spectral cell sorting technology in their labs.
Per an expert familiar with the use of the FACSDiscover S8 Cell Sorters, the instrument was seamlessly configured with respect to the number of lasers and imaging capabilities for his research in cellular biology. Due to the presence of the same sorting speed and software capabilities as the five-laser unit, experiments were extremely scalable on the easy-to-use instrument.
Industry Prospects
Per a report by MarketsandMarkets, the global flow cytometry market was valued at $4.7 billion in 2023 and is anticipated to reach $7 billion by 2028 at a CAGR of 8.3%. Factors like the growing prevalence of cancer and the growing adoption of flow cytometry in clinical applications are likely to drive the market.
Given the market potential, the latest launch is expected to significantly strengthen BD’s business worldwide.
Notable Developments in Life Sciences Arm
In February, BD announced a strategic partnership with Camtech Health to advance cervical cancer screening by offering the first-ever option for women in Singapore to self-collect a sample privately in their homes.
In January, BD announced a strategic collaboration agreement with Techcyte. The tie-up aims to offer an artificial intelligence-based algorithm that guides cytologists and pathologists to efficiently and effectively identify evidence of cervical cancer and pre-cancer using whole-slide imaging.
BD reported its first-quarter fiscal 2024 results, wherein robust performances by the BDB unit were witnessed. The Integrated Diagnostic Solutions (IDS) business unit saw high single-digit growth in Microbiology platforms and strong double-digit growth from Molecular In Vitro Diagnostic assays leveraging the BD COR System and BD Max System install base. During the quarter, the IDS unit received the FDA’s 510(k) clearance for the BD MiniDraw Capillary Blood Collection System.
Price Performance
Shares of BD have lost 2.9% in the past year against the industry’s 9.7% rise and the S&P 500's 27.1% growth.
Image Source: Zacks Investment Research
Zacks Rank & Other Key Picks
Currently, BD carries a Zacks Rank #2 (Buy).
A few other top-ranked stocks in the broader medical space are DaVita Inc. (DVA - Free Report) , Cardinal Health, Inc. (CAH - Free Report) and LeMaitre Vascular, Inc. (LMAT - Free Report) .
DaVita, flaunting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 12.1%. DVA’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 35.6%. You can see the complete list of today’s Zacks #1 Rank stocks here.
DaVita’s shares have gained 61.6% compared with the industry’s 17.6% rise in the past year.
Cardinal Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 14.2%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average being 15.6%.
Cardinal Health has gained 38.1% compared with the industry’s 9.7% rise in the past year.
LeMaitre Vascular, sporting a Zacks Rank of 1 at present, has an estimated long-term growth rate of 14%. LMAT’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 8.9%.
LeMaitre Vascular’s shares have rallied 20.8% compared with the industry’s 2.6% rise in the past year.